Search

The outcome of infants with KMT2A-germline acute lymphoblastic leukaemia (ALL) is superior to that of infants with KMT2A-rearranged ALL but has been inferior to non-infant ALL patients. Here, we describe the outcome and prognostic factors for 167 infants with KMT2A-germline ALL enrolled in the Interfant-06 study.

Cross-presenting dendritic cells (DC) offer an attractive target for vaccination due to their unique ability to process exogenous antigens for presentation on MHC class I molecules. Recent reports have established that these DC express unique surface receptors and play a critical role in the initiation of anti-tumor immunity, opening the way for the development of vaccination strategies specifically targeting these cells.

The Kids Research Institute Australia’s cancer researchers will use funds raised in the name of a brave three-year-old girl to launch a new assault on the devastating form of childhood cancer which took her life.

A pilot clinical study, led in Australia by a The Kids Research Institute Australia and Perth Children's Hospital researcher, has found an immunotherapy drug can dramatically increase survival rates for babies with a rare form of leukaemia, paving the way for a major international clinical trial.

A team of Australian scientists including cancer researchers from The Kids Research Institute Australia have made a crucial breakthrough in understanding how the immune system puts cancer to sleep.

Baxter Hutchinson was diagnosed with two life-threatening brain tumours a year ago, aged 17. Since then he has undergone surgery, radiotherapy and chemotherapy in his journey to beat the cancer.

Projects to improve outcomes for leukaemia patients and reduce skin cancer rates in young Aboriginal people have received funding through Cancer Council WA.

Researchers at The Kids Research Institute Australia have been awarded $4.6 million in national funding from the National Health and Medical Research Council (NHMRC) and Medical Research Future Fund (MRFF) to help support child health research.

Within PF-EPN-A, 1q gain is a marker of poor prognosis, however, it is unclear if within PF-EPN-A additional cytogenetic events exist which can refine risk stratification.

Central nervous system germinomas are treatment-sensitive tumors with excellent survival outcomes. Current treatment strategies combine chemotherapy with radiotherapy (RT) in order to reduce the field and dose of RT. Germinomas originating in the basal ganglia/thalamus have proven challenging to treat given their rarity and poorly defined imaging characteristics. Craniospinal, whole brain, whole ventricle, and focal RT have all been utilized; however, the best treatment strategy remains unclear.